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Background: The challenge of immune senescence has never been addressed in elderly cancer patients. This study
compares the thymic output and peripheral blood telomere length in ≥70 year old cancer patients.
Patients and methods: Fifty-two elderly cancer patients and 39 age-matched controls without personal history of
cancer were enrolled. All patients underwent a Comprehensive Geriatric Assessment (CGA), fromwhich amultidi-
mensional prognostic index (MPI) scorewas calculated. Peripheral blood sampleswere studied for naïve and recent
thymic emigrant (RTE) CD4+ and CD8+ cells by ﬂow cytometry. T-cell receptor rearrangement excision circle
(TREC) levels, telomere length and telomerase activity in peripheral blood cells were quantiﬁed by real-time PCR.
Results: The percentages of CD8+ naïve and CD8+ RTE cells and TREC levels were signiﬁcantly lower in cancer pa-
tients than in controls (p= 0.003, p= 0.004, p = 0.031, respectively). Telomere lengths in peripheral blood cells
were signiﬁcantly shorter in cancer patients than in controls (p = 0.046) and did not correlatewith age in patients,
whereas it did in controls (r =−0.354, p= 0.031). Short telomere (≤median)/low TREC (≤median) proﬁle was
associated with higher risk of cancer (OR= 3.68 [95% CI 1.22–11.11]; p = 0.021). Neither unﬁtness on CGA nor
MPI score were signiﬁcantly related to thymic output or telomere length in either group.
Conclusions: Immune senescence is signiﬁcantlyworse in elderly cancer patients than in age-matched controls. The
low thymic output and the shorter telomeres in peripheral blood cells of cancer patients may reﬂect a pre-existing
condition which facilitates the onset of malignancies in elderly people.© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
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lished by Elsevier Inc. All rights reser25% of Europeans by the year 2030 (Fries, 2003). The incidence of
malignancies increaseswith age, so the number of cancers in the elderly
is expected to increase signiﬁcantly in years to come (American Cancer
Society, 2012). Several studies have shown that elderly patients are less
likely to be treated according to guidelines, and their under-treatment
may be detrimental to both survival and quality of life (Bouchardy
et al., 2003; Dale, 2003; Ng et al., 2005; Sargent et al., 2001). Elderly
cancer patients may beneﬁt from chemotherapy just as much as
younger adults, but at a higher risk of hematological toxicity (Hurria
et al., 2012; Muss et al., 2005, 2007). A better understanding of the
physiological and functional changes that occur with aging will enable
us to improve strategies for treating elderly cancer patients. Since the
aging process coincides with a gradual decline in the functional reserve
of multiple organ systems (Balducci, 2003) the search for laboratory
markers of biological aging and organ reserve should be a priority of
clinical research in the ﬁeld of geriatric oncology.
Over a lifetime, the immune system undergoes a profound remodel-
ing processwithmajor impact onhealth and survival (Fulop et al., 2010;
Grubeck-Loebenstein et al., 2009). Thymic involution and diminishedved.
Table 1
Demographic and clinical characteristics of cancer patients and controls.
All patients,
n (%)
Cancer patients,
n (%)
Controls,
n (%)
Age (yrs)
n 91 (100) 52 (57.2) 39 (42.8)
Median, range 81, 70–92 81, 72–92 80, 70–91
Gender
Male 26 (28.6) 19 (36.5) 7 (17.9)
Female 65 (71.4) 33 (63.5) 32 (82.1)
Performance status (ECOG)
0–1 83 (91.2) 51 (98.1) 32 (82.1)
≥2 8 (8.8) 1 (1.9) 7 (17.9)
Social condition
Home 90 (98.9) 51 (98.1) 39 (100)
Nursing home 1 (1.1) 1 (1.9) 0 (0.0)
Type of assistance
Alone 23 (25.3) 9 (17.3) 14 (35.9)
Family 59 (64.8) 38 (73.1) 21 (53.8)
Others 9 (9.9) 5 (9.6) 4 (10.3)
Caregiver assistance (hours/day)
Median time, range 24, 2–24 24, 2–24 24, 3–24
Tumor stage (TNM)
I – 16 (30.8) –
II – 33 (63.5) –
III – 3 (5.7) –
Modality of diagnosis
Symptoms/self examination – 40 (76.9) –
Screening – 9 (17.3) –
Incidental diagnosis – 3 (5.8) –
Therapeutical choice
Adjuvant therapy as for
younger adults
– 31 (59.6) –
Adapted treatment – 18 (34.6) –
No adjuvant therapy – 3 (5.8) –
Agreement to proposed therapy
Ready – 51 (98.1) –
Patient refusal – 1 (1.9) –
Cause of admission to hospital/
outpatient services
Cardiovascular disease – – 18 (46.2)
Peripheral deep venous thrombosis – – 4 (10.2)
Gastrointestinal inﬂammatory
disorders or bleeding
– – 5 (12.8)
Screening of osteoporosis with
no active comorbidity
– – 12 (30.8)
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contributing to the loss of immune function with age (Berzins et al.,
1998). T cell output begins to decline exponentially from early in life,
and at 75 years of age the immune repertoire appears to be severely
impaired (Douek et al., 1998; Naylor et al., 2005). However, recent
data suggest that the thymus may remain active even late in life,
supplying functional T cells to the periphery (Mitchell et al., 2010;
Nasi et al., 2006).
Measuring T cell receptor rearrangement excision circle (TREC)
levels in peripheral blood lymphocytes has been suggested as
a method for quantifying thymic output (De Rossi et al., 2002;
Douek et al., 1998; Ometto et al., 2002; Zhang et al., 1999).
TRECs are generated by T cell receptor gene rearrangement and
maintained in thymic emigrant cells as DNA episomes. Because
TRECs are not duplicated during mitosis, their concentration is
diluted out with each cell division. The frequency of recent thymic
emigrant (RTE) cells in peripheral blood, identiﬁed by the marker
CD31+ among CD45RA+ naïve T cells (Kimmig et al., 2002),
decreases with aging and correlates well with the decline in
TREC levels (Junge et al., 2007; Kohler et al., 2005). Very little
is known about the relationship between TRECs and cancer,
especially in elderly patients. One study on head and neck cancer
patients, including only a few ≥70 years old, showed that the
age-associated decrease of TREC numbers and naïve T lympho-
cytes was signiﬁcantly greater in cancer patients than in controls,
suggesting altered lymphocyte homeostasis in the former (Kuss
et al., 2005).
The immune system function depends largely on its capacity for
extensive cell division and clonal lymphocyte expansion. Telomere
length and its regulation by telomerase have attracted considerable
attention, due to their potential roles in controlling cell replication
(Blackburn et al., 2006). Telomeres are capping end structures of eu-
karyotic chromosomes essential for protecting chromosome integrity
(Blasco, 2005). Telomeres are progressively shortened during each cell
division due to end-replication problems of DNA polymerase; when a
critical length is reached, the cell undergoes cycle arrest and apoptosis
(Blasco, 2005). Permanent cell growth relies on telomere maintenance,
and certain human cell subsets, as well as most cancer cells, have
telomerase activity which enables telomere elongation (Dolcetti and
De Rossi, 2012). Despite their telomerase activity, most tumor cells
have shorter telomeres than the corresponding normal tissues, and
there is a relationship between short telomeres and genetic instability
(Garcia-Aranda et al., 2006; Rampazzo et al., 2010). Since telomere
shortening reﬂects cell turnover and exposure to oxidative and inﬂam-
matory damage, which are crucial processes in biological aging, it has
been suggested that telomere length serves as an indicator of aging
(Aviv, 2006; Baird, 2006;Wong andCollins, 2003). Telomere shortening
in peripheral blood cells has been associated with a number of chronic
diseases, such as coronary heart disease, hypertension, dementia, obesi-
ty, insulin resistance, and osteoporosis. However, two clinical trials
failed to conﬁrm any relationship between telomere length and frailty
syndrome in elderly non-cancer patients (Collerton et al., 2012; Woo
et al., 2008).
Several studies have investigated the relationship between
telomere length in peripheral blood cells and cancer risk. Although
few manuscripts report that longer telomere length is a risk factor
(e.g. Lan et al., 2013; Svenson et al., 2008), most of the studies
indicate that short telomere lengths are associated with a higher
cancer risk (Bojesen et al., 2013; Martinez-Delgado et al., 2012;
Riegert-Johnson et al., 2012; Shao et al., 2007; Wu et al., 2003). To
date, however, telomere length in peripheral blood cells has been
measured in elderly non-cancer patients and younger cancer pa-
tients, but no data are available for elderly cancer patients. We
present here the results of a prospective observational study provid-
ing the ﬁrst description of immune senescence markers and frailty
scores in elderly cancer patients and age-matched controls.2. Material and methods
2.1. Study design and study population
Patients enrolled in this studywere aged≥70 years, with stages I–III
breast or colorectal cancer, diagnosed during the previous 2 months and
radically resected, consecutively admitted to the Medical Oncology
Units from September 2010 to March 2012. Controls included
patients ≥70 years old with no personal history of cancer, consecu-
tively admitted to the Geriatric Clinic. For both groups, the exclusion
criteria were: any hematological disorders, chronic diseases requir-
ing immunosuppressive treatment, prior immunodeﬁciency, blood
transfusion ≤4 weeks before blood sampling, active infectious dis-
eases, extremely severe comorbidities suggesting a life expectancy
b6 months, or severe cognitive impairment hampering communica-
tion with the physician. The study was approved by the institutional
Ethics Committee and conducted in accordance with the Helsinki
Declaration and Good Clinical Practice guidelines. Written informed
consent was obtained from all patients.
2.2. Clinical assessment
Complete demographic and clinical details were collected at base-
line for each patient (Table 1). At the ﬁrst visit, both cases and controls
underwent traditional comprehensive geriatric assessment (CGA)
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gist, a geriatrician and a psychologist. As reported elsewhere (Basso
and Monfardini, 2004), the CGA included Activities of Daily Living
(ADL), Instrumental Activities of Daily Living (IADL), Short Portable
Mental Status Questionnaire (SPMSQ), and the Mini Mental Status Ex-
amination (MMSE). Comorbidities and their severity were studied ac-
cording to the Cumulative Illness Rating Scale-Comorbidity Index
(CIRS-CI) and Cumulative Illness Rating Scale-Severity Index (CIRS-SI)
(Conwell et al., 1993). Affective status was assessed with the Geriatric
Depression Scale (GDS) (Yesavage et al., 1982–1983). Nutritional status
was exploredwith theMini Nutritional Assessment (MNA) (Guigoz and
Vellas, 1999). Social aspects included household composition, institu-
tionalization, and amount of assistance provided by a care-giver. The
number of drugs taken by patients for concomitant diseases was also
recorded. The CGA results were interpreted as previously reported by
Balducci (2003), classifying patients as ﬁt, vulnerable or frail. A multidi-
mensional prognostic index (MPI) score was also calculated based on
ﬁndings for the ADL, IADL, SPMSQ, CIRS-CI, CIRS-SI, MNA, number of
drugs and social conditions, and assuming a low, moderate or high
mortality risk for MPI ≤0.33, 0.34–0.66, and N0.66, respectively
(Giantin et al., 2013; Pilotto et al., 2008).
2.3. Biomarker analyses
Peripheral blood samples were collected at the time of enrollment,
prior to any oncological medical treatment (endocrine therapy, chemo-
therapy, radiotherapy or immune therapy). Samples were analyzed
for the standard blood parameters (Table 1S, Supplementary data), for
Cytomegalovirus (CMV) status (Table 1S, Supplementary data) and for
the following tests.
2.4. Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from
peripheral blood by centrifugation on a Ficoll-Paque gradient
(Freguja et al., 2011). Cells were stained with the following labeled
monoclonal antibodies (mAbs): anti-CD3 (FITC), anti-CD4 (PerCP),
anti-CD8 (PerCP), anti-CD31 (PE), anti-CD27 (PE) and anti-CD45RA
(APC). Appropriate isotypic controls (mouse IgG1-PE and mouse
IgG2b-APC) were used to assess non-speciﬁc staining. All samples
were analyzed by four-color ﬂow cytometry on a ﬂuorescence-
activated cell sorter (FACS) Calibur (Becton-Dickinson) (Freguja
et al., 2011). Data were processed with CellQuest Pro Software
(Becton-Dickinson) and analyzed with Kaluza® Analysis Software
v.1.2 (Beckman Coulter, Inc.). The percentage of CD45RA+CD27+,
CD45RA−CD27− and CD45RA+CD31+ cells was calculated within
the CD3+CD4+ or CD3+CD8+ gate. CD45RA+CD27+ cells were de-
ﬁned as naïve, CD45RA−CD27− cells as effector memory (Anselmi
et al., 2007) and CD45RA+CD31+ cells as RTE (Kimmig et al., 2002).
2.5. TREC quantiﬁcation
Thymic output in PBMC was studied by measuring TREC levels by
real-time polymerase chain reaction (PCR), exactly as described previ-
ously (De Rossi et al., 2002; Ometto et al., 2002). TREC levels were
expressed as the number of TREC copies per 105 PBMC (Anselmi et al.,
2007; De Rossi et al., 2002).
2.6. Telomere length measurement
Telomere length in PBMC was determined by real-time PCR exactly
as described elsewhere (Rampazzo et al., 2010, 2012), and values
were expressed as relative telomere/single-copy gene (T/S) ratio
(Rampazzo et al., 2010).2.7. Telomerase activity quantiﬁcation
Telomerase activity was quantiﬁed by real-time PCR, as described
elsewhere (Rampazzo et al., 2012) and expressed in relative units (RU).2.8. Statistical analysis
Given the exploratory nature of the present study, a target sample size
of 60 patients (30 patients per group)was calculated according to Browe
(1995). The enrolment target was increased to 90 to ensure an adequate
sample size should some samples be excluded due to laboratory-related
problems.
Differences in geriatric parameters between cancer patients and con-
trols were examined with the Mann–Whitney U test for non-parametric
data and Pearson's χ2 test with odds ratios (OR) and 95% conﬁdence in-
tervals (CI) for nominal data (CGA, MPI, ADL, IADL). The Mann–Whitney
U test was used to compare subsets of lymphocytes, TREC levels, telome-
rase activity and CMV serology in cancer patients and controls. Student's
t-test was used to compare the telomere lengths. Correlations between
age and TREC levels, or telomere length in both groups were analyzed
with Pearson's χ2 test. Spearman's rank correlation was used to analyze
associations between geriatric parameters and TREC levels, telomere
lengths or telomerase activity. TREC levels and telomere length were
also analyzed as dichotomous variables (cut-off: ≤median) and OR
were estimated with a logistic regression model. All statistical analyses
were performed with SPSS Software, Version 18 (SPSS Inc.). All p-
values were two-tailed, and were considered signiﬁcant when lower
than 0.05.3. Results
3.1. Characteristics of the study population
Ninety-one patients, 52 with cancer (26 breast and 26 colorectal
cancer) and 39 controls, were enrolled in the study. Their demographic
and clinical characteristics are listed in Table 1. There were more
women in the control group (82.1%) than among the cancer patients
(63.5%); the latter had better Karnofsky performance status than con-
trols. As established by the study protocol, before enrollment, cancer pa-
tients underwent a thorough radiological assessment to rule out
metastases. According to the TNM staging system, 16 patients (30.8%)
had stage I, 33 (63.5%) stage II, and 3 (5.7%) stage III disease. Thirty-
one patients were prescribed the same adjuvant therapy as for younger
adults, according to good clinical practice, 18 patients received an
adapted treatment, due to problems detected at the CGA, and 3 were
given no adjuvant therapy, due to frailty detected at the CGA and
were only followed up.3.2. Comprehensive geriatric assessment
All cancer patients and controls underwent the full CGA; 17.3% of the
former and 43.6% of the latter were classiﬁed as frail (OR = 0.29, 95% CI
0.10–0.82), while the proportion of vulnerable patients in the two
groups did not differ signiﬁcantly (Table 2). 5.8% of cancer patients
and 23.1% of controls had a moderate MPI (OR= 0.20, 95% CI 0.05–
0.79), and only one control had a severe MPI score. When MPI was cal-
culated as a continuous variable, the median score was signiﬁcantly
lower for cancer patients than for controls (Table 2). In ADL and IADL,
cancer patients tended to have preserved greater physical autonomy
than controls, although the difference was not statistically signiﬁcant
(Table 2). Controls had better cognitive status in both the MMSE and
SPMSQ, but their burden of associated diseases (as shown by CIRS-CI
and CIRS-SI) was higher, as was their use of drugs for these comorbidi-
ties (Table 2).
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The hematological parameters of cancer patients and controls dif-
fered only in their platelet count (Table 1S, Supplementary data). Con-
trols had signiﬁcantly lower levels of nutritional markers, such as total
plasma proteins, triglycerides, and LDL-cholesterol; CRP and IL-6 were
signiﬁcantly higher in controls than in cancer patients (Table 1S, Sup-
plementary data). The overall prevalence of CMV-IgG seropositive indi-
viduals was 96.7%. Antibodies against CMV were found in 49 (94.2%) of
cancer patients and 39 (100%) of controls. No statistical difference was
found between CMV antibody titers between the groups (p= 0.498)
(Table 1S, Supplementary data).3.4. Immune senescence markers
Cancer patients and controls had comparable percentages of
total CD4+ lymphocytes, naïve CD4+CD45RA+CD27+ and RTE
CD4+CD45RA+CD31+ cells (Table 3). By contrast, the median (in-
terquartile) percentages of naïve CD8+CD45RA+CD27+ and RTE
CD8+CD45RA+CD31+ cells were signiﬁcantly lower in cancer patients
than in controls (16.7% [9.3–25.2] versus 24.6% [14.7–33.5]; p = 0.003)
and (34.2% [24.7–46.4] versus 44.9% [36.0–50.7]; p = 0.004), respectively
(Table 3). Notably, the lower percentage of CD8+ naïve cells in cancer
patients was compensated by a higher expansion of CD8+ memory
cells; thus, cancer patients and controls did not differ in terms of their
percentages of total CD8+ cells (Table 3). In particular, among the
CD8+ cell subsets, the CD45RA−CD27− (effector memory) cells were
found to be signiﬁcantly higher in cancer patients than in controls
(21.7% [12.7–31.7] versus 16.3% [10.4–25.0]; p = 0.042). The imbalance
in favor of the CD8memory cell subset in cancer patients was evident
even when the absolute cell count was considered (not shown). For
a few subjects with available frozen samples (11 cancer patients
and 8 controls), markers of immune senescence (CD28−CD57+)Table 2
Scores of geriatric tools in cancer patients and controls.
Geriatric tool All patients Cancer patient
CGA, n (%)
Fit 37 (40.7) 24 (46.2)
Vulnerable 28 (30.7) 19 (36.5)
Frail 26 (28.6) 9 (17.3)
MPI, n (%)
Low 78 (85.7) 49 (94.2)
Moderate 12 (13.2) 3 (5.8)
Severe 1 (1.1) 0 (0.0)
MPI
Median, range 0.25, 0.00–0.69 0.19, 0.00–0.44
Dependencies in ADL, n (%)
No 71 (78.0) 44 (84.6)
≥1 20 (22.0) 8 (15.4)
Dependencies in IADL, n (%)
No 57 (62.6) 36 (69.2)
≥1 34 (37.4) 16 (30.8)
MMSE
Median [IQR] 27.1 [24.4–28.4] 26.2 [24.4–27.
SPMSQ
Median [IQR] 1.0 [0.0–2.0] 1.0 [0.0–2.0]
CIRS-CI
Median [IQR] 3.0 [1.0–4.0] 2.0 [1.0–3.0]
CIRS-SI
Median [IQR] 1.5 [1.3–1.6] 1.4 [1.2–1.5]
GDS
Median [IQR] 3.0 [1.0–6.0] 3.0 [1.2–6.0]
BMI
Median [IQR] 25.7 [24.0–27.4] 25.8 [24.2–26.
Drugs for concomitant diseases
Median [IQR] 5 [3–6] 4 [2–5]
a Pearson's χ2 or Fisher's test.
b Mann–Whitney U test.were investigated. Cancer patients and controls exhibited similar
percentages of CD4+CD28−CD57+, but CD8+ cells with senescent
phenotype tended to be higher in the former (p= 0.082) (Table 3S,
Supplementary data).
TREC levels in PBMCwere signiﬁcantly higher in controls than in can-
cer patients (25.0 [14.0–56.0] versus 16.0 [7.7–31.5] TREC copies/105
PBMC; p = 0.031) (Table 3). TREC levels decreased signiﬁcantly with
increasing age in cancer patients (r =−0.478; p b 0.001), but did not
correlate with age in controls (r = 0.071; p = 0.677) (Fig. 1A).
The mean telomere length in PBMC was signiﬁcantly lower in cancer
patients than in controls; the former had a mean (±standard deviation
(SD)) telomere length of 1.09 ± 0.31 T/S versus 1.22 ± 0.30 T/S in
controls, p = 0.046 (Table 3). Telomere length correlated inversely
with age in controls (r =−0.354, p = 0.031), but not in cancer pa-
tients (r =−0.011, p = 0.938) (Fig. 1B). Telomerase activity was
signiﬁcantly higher in cancer patients, being detected in 38/52
patients (73.1%; median value 14.6 RU) and 20/38 controls (52.6%;
median value 1.4 RU); p = 0.003. Telomerase activity was not inﬂu-
enced by age in either group.
TREC was deﬁned as high or low, and telomere length as long or
short according to their values above and below themedian, respective-
ly. Subjects with TREC low/telomere short proﬁle were at higher risk of
cancer than subjects with only low TREC or short telomere (Table 4).3.5. Relationship between TREC levels, telomere length and
geriatric characteristics
In the control group, CIRS-SI was the only tool which revealed a
signiﬁcant positive association with TREC level (r = 0.45, p = 0.01) and
telomere length (r = 0.35, p = 0.03), whereas it had a signiﬁcant nega-
tive correlationwith the number of drugs taken for concomitant diseases
(r =−0.39, p = 0.02) (Table 2S, Supplementary data). No relationship
emerged between telomere length, thymic output and geriatric featuress Controls OR (95% CI) p-Value
13 (33.3) 1
9 (23.1) 1.14 (0.40–3.24) 0.801a
17 (43.6) 0.29 (0.10–0.82) 0.020a
29 (74.3) 1
9 (23.1) 0.20 (0.05–0.79) 0.022a
1 (2.6) b0.01 nsa
0.25, 0.06-0.69 – 0.001a
27 (69.2) 1
12 (30.8) 0.41 (0.15–1.14) 0.790a
21 (53.8) 1
18 (46.2) 0.52 (0.22–1.23) 0.133a
3] 28.3 [26.4–29.3] – 0.001b
0.0 [0.0–2.0] – 0.013b
3.0 [2.0–4.0] – 0.032b
1.6 [1.4–1.8] – b0.001b
3.0 [1.0–6.0] – 0.888b
9] 25.0 [23.0–28.6] – 0.911b
5 [4–8] – 0.003b
Table 3
Thymic output and telomere length in cancer patients and controls.
Parameter All patients
Median [IQR]
Cancer patients
Median [IQR]
Controls
Median [IQR]
p-Value
% CD3+ 54.3 [40.8–65.2] 53.6 [37.8–65.5] 56.3 [41.8–65.2] 0.560 a
% CD4+ 35.5 [25.6–49.1] 35.0 [21.1–46.7] 35.6 [26.6–51.8] 0.389 a
% CD8+ 15.7 [10.1–22.4] 15.4 [9.7–22.6] 16.4 [10.5–22.8] 0.717 a
% naïve, CD4+CD45RA+CD27+ 34.0 [22.5–48.5] 29.6 [17.9–48.3] 38.0 [27.0–49.8] 0.076 a
% naïve, CD8+CD45RA+CD27+ 20.5 [10.9–29.5] 16.7 [9.3–25.2] 24.6 [14.7–33.5] 0.003 a
% RTE, CD4+CD45RA+CD31+ 21.3 [14.2–33.4] 20.3 [10.4–32.0] 23.3 [16.8–33.5] 0.176 a
% RTE, CD8+CD45RA+CD31+ 37.6 [29.1–48.9] 34.2 [24.7–46.4] 44.9 [36.0–50.7] 0.004 a
TREC copy number/105 PBMC 19.0 [10.1–37.0] 16.0 [7.7–31.5] 25.0 [14.0–56.0] 0.031 a
Telomere length (T/S ratio)c 1.15 ± 0.30 1.09± 0.31 1.22± 0.30 0.046 b
Telomerase activity
n positive/n tested 58/90 38/52 20/38
Relative units 5.6 [0.0–26.0] 14.6 [0.0–36.8] 1.4 [0.0–6.4] 0.003a
a Mann–Whitney U test.
b Student's t-test.
c Data are expressed as mean ± SD.
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of unﬁtness at CGA (not shown) nor theMPI score (Table 2S, Supplemen-
tary data) correlated signiﬁcantly with thymic output or telomere length
in either group. Among the controls, TREC levels correlated positively
with IL-6 (r = 0.34, p = 0.04) and negatively with total plasma proteinFig. 1.Correlation between age and (A) TREC levels and (B) telomere lengths in cancer
patients and controls. Panel (A): TREC levels decline with age in peripheral blood cells
of cancer patients (r =−0.478, p b 0.001), but not in controls (r = 0.071, p = 0.677). Panel
(B): telomere lengths decrease with age in peripheral blood cells of controls (r =−0.354,
p = 0.031), but not in cancer patients (r =−0.011, p = 0.938).levels (r =−0.38, p = 0.02). Neither of these correlations emerged in
the cancer patients (data not shown).
4. Discussion
This is the ﬁrst study aiming to shed light on two essential aspects of
the aging process (thymic output and telomere length in peripheral
blood cells) in elderly cancer patients. We found that 70- to 92-year-
old cancer patients had signiﬁcantly lower TREC levels, lower percent-
ages of naïve and RTE CD8+ T lymphocytes, and a more expanded
CD8+ memory cell subset than age-matched controls. These results
are partially consistent with those of a small trial in which head and
neck cancer patients (most of them under 70 years old) revealed
lower TREC levels than controls (Kuss et al., 2005). The expansion of
memory CD8+ cells, particularly those with effector phenotype, is also
consistent with the ﬁndings of two recent studies of breast cancer pa-
tients (Hueman et al., 2007; Poschke et al., 2012). The shift from naïve
T cells to memory cells was probably due to greater stimulation by
tumor antigens; as CD8+ T cells are the key components of tumor
immune surveillance, the tumor-induced dysfunction may be more
evident in the CD8-cell subset than in the CD4-cell compartment
(Klebanoff et al., 2006; Williams and Bevan, 2007).
Our ﬁndings conﬁrm reports by other authors that thymic activity
does not stop completely beyond 70 years of age (Mitchell et al., 2010;
Nasi et al., 2006). Notably, while TREC levels in cancer patients dropped
signiﬁcantly with increasing age, they remained relatively constant in
controls. Thymic output may compensate for the loss of peripheral
blood lymphocytes in elderly patients, but this homeostatic phenomenonTable 4
TREC and telomere proﬁle on cancer patients and controls.
Cancer patients
n (%)
Controls
n (%)
OR (95% CI) p-
Value
TREC levelsa
TREC high 20 (40.0) 23 (62.2) 1
TREC low 30 (60.0) 14 (37.8) 2.46
(1.03–5.90)
0.043
Telomere lengthb
T/S long 21 (40.4) 23 (62.2) 1
T/S short 31 (59.6) 14 (37.8) 2.43
(1.02–5.76)
0.045
TREC levels & telomere length
Othersc 31 (62.0) 30 (85.7) 1
TREC low & T/S short 19 (38.0) 5 (14.3) 3.68 (1.22–
11.11)
0.021
a TREC low: TREC≤median, TREC high: TREC Nmedian.
b T/S short: T/S≤median, T/S long: T/S Nmedian (the median value is coincident with
the mean value).
c Others: TREC high & T/S long, TREC low & T/S long and TREC high & T/S short.
1441C. Falci et al. / Experimental Gerontology 48 (2013) 1436–1442seems to disappear in cancer patients. In our study, the control group in-
cluded a higher proportion of frail patients, with higher average MPI
scores and more chronic diseases and comorbidities than the cancer pa-
tients. Levels of pro-inﬂammatory cytokine IL-6 were also signiﬁcantly
higher in controls than in cancer patients. Systemic inﬂammation and
loss of peripheral blood cells may stimulate thymic output, which plays
an important role in immunological homeostasis. In fact, TREC levels
did correlate signiﬁcantly with CIRS-CI in controls, but not in cancer pa-
tients. The imbalance between the two groups in terms of their geriatric
conditions reinforces the magnitude of the difference observed for TREC
levels between cancer patients and controls. While the hypothesis of
immune homeostasis may justify a higher thymic output in controls,
the lower age-related TREC levels seen in cancer patients may point to
a pre-existing condition, favoring immune escape and the onset ofmalig-
nant disease.
In agreementwith the lower percentage of CD8+ naive and RTE cells
in cancer patients than in controls, the former tended to have a higher
percentage of CD8+ immune senescent cells. Several data indicate that
latent CMV infection leads to signiﬁcant changes in the CD8+ repertoire,
and it may be an important driver of immune senescence (Almanzar
et al., 2005; Solana et al., 2012). The above results are unlikely to be
due to CMV infection, because all except three cancer patients were
CMV-positive and with similar titers of anti-CMV antibodies.
As regards telomere length, there are many data available on the re-
lationship between telomere length and aging-associated changes and
chronic diseases (Aviv, 2006; Baird, 2006; Wong and Collins, 2003),
but data are lacking for elderly cancer patients. Our study showed that
cancer patients' telomeres in PBMC were signiﬁcantly shorter than
those seen in controls. In addition, while control patients' telomeres
became shorter with age, as expected according to previous studies
(Blasco, 2005; Der et al., 2012; Steenstrup et al., 2013), no such relation-
ship between age and telomere length was seen in our cancer patients.
This difference cannot be explained by lower telomerase activity,
because it was detected in the PBMC of most cancer patients. The fact
that controls scored worse on the severity and comorbidity indexes
than cancer patients clearly highlights the magnitude of the difference
in telomere length between the groups.
Several studies have found shorter telomeres in tumor cells than in
surrounding non-cancer cells (Bisofﬁ et al., 2006; Rampazzo et al.,
2010), but the intriguing ﬁnding of shorter telomeres in PBMC cannot
be explained by the presence of cancer cells in peripheral blood. Our
cancer patients had radically resected early breast or colorectal cancer,
and had undergone thorough radiological assessment to exclude both
persistent local disease and distant metastases. As reported elsewhere
(Franken et al., 2012; Shimada et al., 2012), the number of epithelial
cells detectable in the peripheral blood of patients with early breast or
colorectal cancer is so small that it cannot inﬂuence telomere length
or telomerase activity. We surmised that our control patients' longer
telomeres were related to their higher proportion of naïve CD8+ cells.
To explore this issue, we estimated telomere length separately in
CD8+ naïve and CD8+ memory cells from three cancer patients: the
two subsets had a similar telomere length, indicating that the shorter
telomeres cannot be explained by an excessive replication/expansion
of the memory cell subset (not shown). We therefore suggest that
telomere length in peripheral blood cells reﬂects the more advanced
biological aging of the immune system in cancer patients than in
controls, a pre-existing condition which facilitates the onset of cancer
in the former.
Neither thymic output nor telomere length correlated with the
results of the CGA or MPI scores in our study population. These
results are consistent with studies in elderly-non cancer patients,
which found no association between frailty indexes and telomere
length (Collerton et al., 2012; Woo et al., 2008). Therefore, the rela-
tionship between these markers and immune senescence and aging
cannot be extrapolated to the functional level represented by the
geriatric assessment of frailty.5. Conclusions
This exploratory study is the ﬁrst to ﬁnd that elderly cancer patients
have signiﬁcantly lower thymic output and shorter telomeres in their
peripheral blood cells than age-matched non-cancer patients; these re-
sults indicate that immune senescence may hamper the ability of the
immune system to prevent cancer initiation and/or control of tumor
progression. Overall, these ﬁndings suggest the hypothesis, which
would need to be tested in a larger study, that elderly people with
shorter telomeres and lower thymic output are at higher risk of devel-
oping cancer.
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